Physician profile
Daniel B Phillips
NPI 1720042732
$203.97
in general payments reported to CMS, 2019-2025
11 companies · $15.40 in 2025
The $15.40 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $11.51 · 2021: $25.47 · 2024: $24.82 · 2025: $15.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.69 | 2019-2021 | |
| Hologic Sales and Service, LLC | $24.82 | 2024 | Aptima |
| Sanofi Pasteur INC. | $20.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.44 | 2019 | |
| Astellas Pharma US INC | $15.50 | 2019 | |
| Smith+Nephew, INC. | $15.40 | 2025 | Regranex, Collagenase Santyl |
| Pfizer INC. | $14.82 | 2019 | |
| Glaxosmithkline, LLC. | $14.37 | 2019 | |
| Therapeuticsmd, INC. | $14.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.